GET DAILY SIGNALSQuest Diagnostics (DGX) Delivers Q3 2026 Beat with +10% Revenue Growth
Key Takeaways
- Quest Diagnostics reported third-quarter 2026 revenue of $3.1 billion, up 10% year over year, exceeding Wall Street estimates.
- Adjusted earnings per share (EPS) came in at $3.00, up 15.4% from $2.60 a year earlier and ahead of consensus expectations.
- Total testing volume, measured by requisitions, rose 14.5% year over year, with organic volume up 14.4%.
- Management raised and narrowed its full-year 2026 guidance for both revenue and EPS, citing sustained demand across physician, hospital, and consumer channels.
- Despite the beat and raised outlook, shares traded modestly lower in early trading following the release.
Earnings Context and Why It Matters
Quest Diagnostics is one of the largest providers of diagnostic information services in the United States, processing roughly one-third of the adult population's lab tests each year. Its quarterly results are closely watched as a barometer of overall healthcare utilization and consumer health trends. Heading into the report, investors were focused on whether strong testing demand could offset pressure on pricing and reimbursement, particularly as the company integrates its Corewell Health and Fresenius Medical Care partnerships. The third-quarter update carried added weight because it signaled whether Quest's growth momentum and margin trajectory could support another increase to its annual outlook. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the three months ended September 30, 2026, Quest Diagnostics reported consolidated revenue of $3.1 billion, a 10% increase from the prior-year quarter. Diagnostic Information Services revenue grew 10.2% year over year, including 10.1% organic growth. The results exceeded the Zacks Consensus Estimate for revenue by roughly 1.7%.
Reported (GAAP) EPS was $2.78, up from $2.16 in the year-ago period. On an adjusted basis, EPS was $3.00, a 15.4% increase from $2.60 a year earlier and above the consensus estimate of $2.85, representing a beat of more than 5%.
Total testing volume climbed 14.5% year over year, with organic volume up 14.4%. The Corewell Health and Fresenius Medical Care relationships contributed 9.5% of volume in the quarter. Revenue per requisition declined 4.2% due to that business mix, but rose 1.7% after adjusting for it. Reported operating income was $479 million, or 15.5% of revenue, compared with $386 million, or 13.7%, a year earlier. Adjusted operating income reached $517 million, or 16.7% of revenue, a 40-basis-point margin improvement. From what I see, these volume trends highlight steady underlying demand.
Market Reaction and Investor Sentiment
Despite a solid earnings and revenue beat, plus raised guidance, Quest Diagnostics shares edged lower in pre-market and early trading following the announcement. That reaction suggests investors had largely priced in the company's momentum and may have been looking for an even stronger forward signal. Sentiment around the stock remains broadly constructive, supported by sustained demand across testing channels and productivity gains from automation and artificial intelligence. However, concerns about reimbursement pressures and the revenue-per-requisition decline tied to new partnerships tempered enthusiasm.
Forward Outlook and Key Factors to Monitor
Quest Diagnostics raised and narrowed its full-year 2026 guidance following the third quarter. The company now expects revenue between $12.065 billion and $12.105 billion, representing growth of 9.3% to 9.7%, and adjusted EPS in a range of $11.25 to $11.35. Cash from operations is projected at approximately $1.9 billion, with capital expenditures of roughly $550 million.
Looking further ahead, investors should watch the company's commentary on reimbursement changes. Management estimates that PAMA (the Protecting Access to Medicare Act) rate-setting framework could reduce 2027 revenue by about 1%, with a cumulative impact of less than 1.3% from 2027 through 2029. Quest continues to advocate for the RESULTS Act to reform PAMA data collection.
Other factors to monitor include the continued ramp of the Corewell Health and Fresenius Medical Care collaborations, the growth trajectory of the consumer health segment, and progress on the Project Nova technology initiative. Cost trends, including wage inflation and fuel expenses, will also remain relevant to margin expansion. Quest plans to provide full 2027 guidance alongside its fourth-quarter results and will host its Investor Day on March 25, 2027. I’m watching this closely as these elements could shape the stock’s path in the quarters ahead.
Using AI Tools in My Research Process
In my view, tools like Tickeron’s AI Screener can help investors quickly compare performance metrics across the healthcare sector and identify patterns that align with earnings trends. I find it useful for refining ideas around names like DGX without spending hours on manual analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DGX in +0.47% Uptrend, growing for three consecutive days on November 12, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DGX advanced for three days, in 193 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on DGX as a result. In 46 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for DGX just turned positive on October 15, 2026. Looking at past instances where DGX's MACD turned positive, the stock continued to rise in 20 of 42 cases over the following month. The odds of a continued upward trend are 48%.
DGX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DGX crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.
DGX broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DGX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.754) is normal, around the industry mean (67.298). P/E Ratio (26.796) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.546) is also within normal values, averaging (3.473). DGX's Dividend Yield (0.013) is considerably higher than the industry average of (0.002). P/S Ratio (2.404) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. DGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What Does the SPY ETF, the SPDR S&P 500 ETF Trust, Contain?
6 Benefits of Finding Stock Chart Patterns in Real Time
AI Trading Bots: Top 10 Swing Traders, Signals Only, on December 5, 2024
Cyclacel Pharmaceuticals ( CYCC ) Stock Soars 251.95% in Five Days: Catalysts, Correlations, and AI-Driven Trading Opportunities
PepsiCo ( PEP ) Soars with 37.16% Expected Earnings Growth in Q2 2025: Catalysts, Correlations, and Future Potential
General Information
a provider of diagnostic testing and information services
Industry MedicalSpecialties
Advertisement